Comment on Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study. [Lancet Oncol. 2018]
Pertuzumab therapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer / Roviello G.; Generali D.. - In: THE LANCET ONCOLOGY. - ISSN 1470-2045. - ELETTRONICO. - 19:(2018), pp. 1270-1272. [10.1016/S1470-2045(18)30512-6]
Pertuzumab therapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer
Roviello G.
;
2018
Abstract
Comment on Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study. [Lancet Oncol. 2018]
File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
